Cellular FXIII in Human Macrophage-Derived Foam Cells.

atherosclerotic plaque cross-linking enzyme-modified LDL factor XIII foam cells macrophages oxidized LDL transglutaminase vascular smooth muscle cells

Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
02 Mar 2023
Historique:
received: 30 01 2023
revised: 24 02 2023
accepted: 01 03 2023
entrez: 11 3 2023
pubmed: 12 3 2023
medline: 15 3 2023
Statut: epublish

Résumé

Macrophages express the A subunit of coagulation factor XIII (FXIII-A), a transglutaminase which cross-links proteins through Nε-(γ-L-glutamyl)-L-lysyl iso-peptide bonds. Macrophages are major cellular constituents of the atherosclerotic plaque; they may stabilize the plaque by cross-linking structural proteins and they may become transformed into foam cells by accumulating oxidized LDL (oxLDL). The combination of oxLDL staining by Oil Red O and immunofluorescent staining for FXIII-A demonstrated that FXIII-A is retained during the transformation of cultured human macrophages into foam cells. ELISA and Western blotting techniques revealed that the transformation of macrophages into foam cells elevated the intracellular FXIII-A content. This phenomenon seems specific for macrophage-derived foam cells; the transformation of vascular smooth muscle cells into foam cells fails to induce a similar effect. FXIII-A containing macrophages are abundant in the atherosclerotic plaque and FXIII-A is also present in the extracellular compartment. The protein cross-linking activity of FXIII-A in the plaque was demonstrated using an antibody labeling the iso-peptide bonds. Cells showing combined staining for FXIII-A and oxLDL in tissue sections demonstrated that FXIII-A-containing macrophages within the atherosclerotic plaque are also transformed into foam cells. Such cells may contribute to the formation of lipid core and the plaque structurization.

Identifiants

pubmed: 36902231
pii: ijms24054802
doi: 10.3390/ijms24054802
pmc: PMC10002485
pii:
doi:

Substances chimiques

Factor XIII 9013-56-3
Lipoproteins, LDL 0
Peptides 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Références

J Exp Med. 1984 Jan 1;159(1):114-25
pubmed: 6141210
J Thromb Haemost. 2011 Jan;9(1):9-20
pubmed: 20880254
Thromb Res. 1985 Feb 1;37(3):401-10
pubmed: 2859670
Cell Immunol. 2004 Apr;228(2):81-90
pubmed: 15219459
Circulation. 2014 Apr 15;129(15):1551-9
pubmed: 24481950
Eur J Cell Biol. 1985 Jul;38(1):171-3
pubmed: 3896808
Thromb Haemost. 1988 Apr 8;59(2):231-5
pubmed: 2898817
Front Cardiovasc Med. 2022 Apr 13;9:845942
pubmed: 35498045
Cell Stem Cell. 2020 Jan 2;26(1):81-96.e4
pubmed: 31883835
J Immunol Methods. 2001 Dec 1;258(1-2):127-35
pubmed: 11684129
Int J Mol Sci. 2021 Jun 22;22(13):
pubmed: 34206377
J Clin Invest. 1985 Aug;76(2):528-34
pubmed: 2863285
Semin Thromb Hemost. 2016 Jun;42(4):422-8
pubmed: 27019464
Thromb Haemost. 2001 May;85(5):845-51
pubmed: 11372678
Int J Mol Sci. 2021 Mar 17;22(6):
pubmed: 33802692
Physiol Rev. 2011 Jul;91(3):931-72
pubmed: 21742792
Med Sci (Basel). 2018 Dec 11;6(4):
pubmed: 30545030
Circ Res. 1998 Aug 10;83(3):264-9
pubmed: 9710118
J Thromb Haemost. 2019 Jan;17(1):19-30
pubmed: 30489000
Semin Thromb Hemost. 2016 Jun;42(4):445-54
pubmed: 27056150
Int J Mol Sci. 2021 Jun 19;22(12):
pubmed: 34205443
Mediators Inflamm. 2013;2013:198193
pubmed: 24062612
Front Cardiovasc Med. 2022 Feb 14;9:777822
pubmed: 35237673
Cell Mol Life Sci. 2005 Sep;62(18):2132-9
pubmed: 16132226
Antioxidants (Basel). 2021 Mar 26;10(4):
pubmed: 33810295
Thromb Haemost. 2012 Dec;108(6):1172-9
pubmed: 23052999
Eur J Pharmacol. 2017 Dec 5;816:14-24
pubmed: 28989084
Thromb Haemost. 2010 Oct;104(4):709-17
pubmed: 20664907
Atherosclerosis. 2016 May;248:170-8
pubmed: 27038418
Circulation. 1995 Sep 1;92(5):1355-74
pubmed: 7648691
Cardiovasc Res. 2012 Jul 15;95(2):156-64
pubmed: 22406749
Blood. 2010 Apr 1;115(13):2674-81
pubmed: 20086247
Arterioscler Thromb Vasc Biol. 1999 Oct;19(10):2348-54
pubmed: 10521363

Auteurs

Laura Somodi (L)

Division of Clinical Laboratory Science, Department of Laboratory Medicine, Faculty of Medicine, University of Debrecen, 98 Nagyerdei krt, 4032 Debrecen, Hungary.
Kálmán Laki Doctoral School of Biomedical and Clinical Sciences, University of Debrecen, 98 Nagyerdei krt, 4032 Debrecen, Hungary.

Emőke Horváth (E)

Pathology Service, County Emergency Clinical Hospital of Targu Mures, 50 Gheorghe Marinescu Street, 540136 Targu Mures, Romania.
Department of Pathology, Faculty of Medicine, George Emil Palade University of Medicine, Pharmacy, Science, and Technology of Targu Mures, 38 Gheorghe Marinescu Street, 540142 Targu Mures, Romania.

Helga Bárdos (H)

Department of Public Health and Epidemiology, Faculty of Medicine, University of Debrecen, 26 Kassai út, 4028 Debrecen, Hungary.

Barbara Baráth (B)

Division of Clinical Laboratory Science, Department of Laboratory Medicine, Faculty of Medicine, University of Debrecen, 98 Nagyerdei krt, 4032 Debrecen, Hungary.

Dávid Pethő (D)

Kálmán Laki Doctoral School of Biomedical and Clinical Sciences, University of Debrecen, 98 Nagyerdei krt, 4032 Debrecen, Hungary.
Division of Nephrology, Department of Medicine, Faculty of Medicine, University of Debrecen, 98 Nagyerdei krt, 4032 Debrecen, Hungary.

Éva Katona (É)

Division of Clinical Laboratory Science, Department of Laboratory Medicine, Faculty of Medicine, University of Debrecen, 98 Nagyerdei krt, 4032 Debrecen, Hungary.

József Balla (J)

Division of Nephrology, Department of Medicine, Faculty of Medicine, University of Debrecen, 98 Nagyerdei krt, 4032 Debrecen, Hungary.
ELKH-UD Vascular Pathophysiology Research Group 11003, University of Debrecen, 4032 Debrecen, Hungary.

Nicola J Mutch (NJ)

Aberdeen Cardiovascular and Diabetes Centre, Institute of Medical Sciences, School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Aberdeen AB25 2ZD, UK.

László Muszbek (L)

Division of Clinical Laboratory Science, Department of Laboratory Medicine, Faculty of Medicine, University of Debrecen, 98 Nagyerdei krt, 4032 Debrecen, Hungary.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH